Welcome to our dedicated page for XPHYF news (Ticker: XPHYF), a resource for investors and traders seeking the latest updates and insights on XPHYF stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect XPHYF's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of XPHYF's position in the market.
XPhyto Therapeutics Corp (CSE:XPHY / OTCQB:XPHYF / FSE:4XT) will present at the virtual LD Micro Main Event (XIII) on December 15, 2020, at 1:20 p.m. Eastern time. CEO Hugh Rogers will lead the presentation, and a live audio webcast will be available. Recent highlights include the development of an RT-PCR test for COVID-19 detection and partnerships for psilocybin API production. XPhyto focuses on drug delivery, diagnostics, and emerging pharmaceuticals, with operations in North America and Europe, targeting regulatory approvals in European markets.
XPhyto Therapeutics Corp (CSE:XPHY, OTCQB:XPHYF) announced an agreement for a $3 million issuance of unsecured convertible debentures. The investor specializes in manufacturing medical products in Europe and the Middle East. Proceeds will fund development of oral dissolvable and transdermal drug formulations, diagnostic products, and psychedelic APIs. The debentures carry an 8% interest rate, maturing in two years, and are convertible into common shares at $1.77. The offering awaits CSE approval, with a statutory hold period applicable.
XPhyto Therapeutics Corp. (CSE:XPHY, OTCQB:XPHYF) has expanded its exclusive development agreement with Prof. Dr. Raimar Löbenberg to include psychedelic compounds such as psilocybin, mescaline, LSD, MDMA, and DMT. This addition is aimed at leveraging the therapeutic potential of these compounds for treating mental health issues. The agreement enhances XPhyto's capabilities in developing standardized drug formulations for clinical use. Dr. Löbenberg, an expert in biopharmaceutics, emphasizes the goal of creating precise drug delivery systems. The psychedelic drugs are gaining recognition for their potential benefits in mental health treatments.
XPhyto Therapeutics Corp (CSE:XPHY, OTCQB:XPHYF) has appointed Per S. Thoresen to its board of directors, effective immediately. Thoresen brings 25 years of pharmaceutical experience, including executive roles at major firms and a successful tenure as managing director at Nycomed Pharma. The company also announced a strategic partnership with CorpCann AS, enhancing its Europe-focused strategy. Thoresen will receive 250,000 stock options as part of his role. This leadership change aims to bolster XPhyto’s advancement in drug delivery and diagnostics, with products nearing commercialization.
XPhyto Therapeutics Corp has appointed Per S. Thoresen, an experienced pharma executive, to its board, effective immediately. Thoresen brings 25 years of experience, including a role as managing director at Nycomed Pharma, acquired by Takeda for approximately USD $14B. His expertise is expected to enhance XPhyto's strategy as several products near commercialization. Additionally, XPhyto has engaged with CorpCann AS, which will support its European-focused growth strategy. As part of the appointment, Thoresen received 250,000 stock options exercisable at $1.80 over five years.
XPhyto Therapeutics Corp. (CSE:XPHY, OTC:XPHYF) has announced a rapid 25-minute RT-PCR test for COVID-19, developed by its partner 3a-Diagnostics. This test, alongside a 15-minute rapid test, is set for commercial launch in Europe in Q1 2021. The RT-PCR system, designed for laboratory use, promises results in under 25 minutes with minimal equipment. Validation studies are planned in Germany for Q4 2020. The partnership includes exclusive commercialization rights for both testing systems, advancing XPhyto's position in the diagnostics market.
XPhyto Therapeutics Corp (CSE:XPHY / OTCQB:XPHYF) announced developments from its German subsidiary, Vektor Pharma TF GmbH, regarding a new oral disintegrating film (ODF) dosage formulation for a major generic drug company.
Vektor recently completed manufacturing clinical trial materials for evaluation. The ODF technology supports quick adjustments to formulation based on various active pharmaceutical ingredients (APIs).
As the global thin film drug market is projected to reach USD $29.2 billion by 2024, XPhyto is working on enhancing drug delivery systems and plans to update on its COVID-19 screening test development soon.
XPhyto Therapeutics Corp (CSE:XPHY, OTC:XPHYF) announced advancements in its oral disintegrating film (ODF) drug delivery programs, focusing on cannabidiol (CBD) and tetrahydrocannabinol (THC). The company’s subsidiary, Vektor Pharma, is developing ODFs designed to enhance bioavailability and provide faster drug action. Initial data shows a 5-fold increase in CBD bioavailability compared to oil-based methods. The global thin film drug market is projected to reach USD $29.2 billion by 2024. XPhyto is exploring additional ODF opportunities, including a 1:1 CBD/THC formula for MS-induced spasticity.
XPhyto Therapeutics Corp. (CSE:XPHY) (OTCQB:XPHYF) will present at the Virtual Life Sciences Forum on September 17, 2020, at 1:00 PM Eastern Time. CEO Hugh Rogers will discuss developments in Germany regarding a rapid COVID-19 screening test and innovative drug delivery methods. The company collaborates with 3a-Diagnostics GmbH on a point-of-care test for COVID-19 viral RNA detection. Additionally, XPhyto is advancing dosage forms for conventional and cannabis-based narcotics. The event is open to investors, with registration available online.
XPhyto Therapeutics Corp (CSE:XPHY / OTCQB:XPHYF / FSE:4XT) has provided an update on its rapid COVID-19 screening test development in partnership with 3a-Diagnostics GmbH.
The test aims to detect COVID-19 viral RNA from saliva and swab samples. Following successful validation of a prototype, the company anticipates advanced prototype production and usability testing in Q4 2020. XPhyto is also developing tests for other viruses, with funding from the German Federal Ministry of Education and Research. While the scientific landscape surrounding COVID-19 continues to evolve, XPhyto is focusing on low-cost, decentralized screening solutions.
FAQ
What is the market cap of XPHYF (XPHYF)?
